E-LIB Suche - Ergebnisse für: Campistol Plana, Josep Maria

1

P0664CKDSENS, A NOVEL HEALTHCARE PLATFORM FOR CHRONIC KIDNE..:

Campistol Plana, Josep Maria ; Maceira, Adrià ; Novell, Marta...
Nephrology Dialysis Transplantation. 35 (2020) Supplement_3 - p. , 2020

Link: https://doi.org/10.1093/..

2

Immunogenicity and Safety of the Adjuvanted Recombinant Zos..:

Vink, Peter ; Ramon Torrell, Josep Maria ; Sanchez Fructuoso, Ana...
Clinical Infectious Diseases. , 2019

Link: https://doi.org/10.1093/..

3

#3006 Therapeutic apheresis in Fabry disease:

Ugalde-Altamirano, Jessica ; Juarez, Jordi Rovira ; Plana, Josep Maria Campistol...
Nephrology Dialysis Transplantation. 39 (2024) Supplement_1 - p. , 2024

Link: https://doi.org/10.1093/..

4

#2908 Renal progenitor cells an early non-invasive biomarke..:

Ugalde-Altamirano, Jessica ; Juarez, Jordi Rovira ; Tubita, Valeria...
Nephrology Dialysis Transplantation. 39 (2024) Supplement_1 - p. , 2024

Link: https://doi.org/10.1093/..

5

Long-term efficacy and safety of inotersen for hereditary t..:

Brannagan, Thomas H. ; Coelho, Teresa ; Wang, Annabel K....
Journal of Neurology. 269 (2022) 12 - p. 6416-6427 , 2022

Link: https://doi.org/10.1007/..

6

FC 110: Survival Benefit of Preemptive Simultaneous Pancrea..:

Montagud-Marrahi, Enrique ; Cuadrado, Elena ; Hermida, Evelyn...
Nephrology Dialysis Transplantation. 37 (2022) Supplement_3 - p. , 2022

Link: https://doi.org/10.1093/..

7

Characteristics of Patients with Late- vs. Early-Onset Val3..:

Waddington-Cruz, Márcia ; Wixner, Jonas ; Amass, Leslie...
Neurology and Therapy. 10 (2021) 2 - p. 753-766 , 2021

Link: https://doi.org/10.1007/..

8

Efficacy and safety with >3 years of inotersen treatment fo..:

Coelho, Teresa ; Whelan, Carol ; Conceição, Isabel...
Journal of the Neurological Sciences. 429 (2021) - p. 117867 , 2021

Link: https://doi.org/10.1016/..

9

2483. Twelve-Month Immunogenicity and Safety of an Adjuvant..:

Vink, Peter ; Torrell, Josep Maria Ramon ; Sanchez-Fructuoso, Ana I...
Open Forum Infectious Diseases. 5 (2018) suppl_1 - p. S744-S745 , 2018

Link: https://doi.org/10.1093/..

10

Long-term efficacy and safety of inotersen for hereditary t..:

Brannagan, Thomas H ; Coelho, Teresa ; Wang, Annabel K...
10.1007/s00415-022-11276-8. , 2022

Link: https://hdl.handle.net/1..

11

Immunogenicity and Safety of the Adjuvanted Recombinant Zos..:

Vink, Peter ; Ramon Torrell, Josep Maria ; Sanchez Fructuoso, Ana...
http://hdl.handle.net/10668/13670. , 2020

Link: http://hdl.handle.net/10..

12

Early data on long‐term efficacy and safety of inotersen in..:

Brannagan, T. H ; Wang, A. K ; Coelho, T...
https://onlinelibrary.wiley.com/doi/10.1111/ene.14285. , 2020

Link: http://hdl.handle.net/10..

13

Cytomegalovirus prevention strategies in seropositive kidne..:

Fernandez Ruiz, Mario ; Arias Rodriguez, Manuel ; Campistol Plana, Josep María...
https://onlinelibrary.wiley.com/doi/10.1111/tri.12586. , 2015

Link: https://uvadoc.uva.es/ha..

14

Renal transplantation in the modern immunosuppressive era i..:

Morales Cerdán, Jose Maria ; Marcén Letosa, Roberto ; Andrés Belmonte, Amado...
https://www.kidney-international.org/article/S0085-2538(15)53246-8/fulltext. , 2008

Link: https://uvadoc.uva.es/ha..

15

Long-term efficacy and safety of inotersen for hereditary t..:

Brannagan, Thomas H ; Coelho, Teresa ; Wang, Annabel K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618524/. , 2022

Link: http://www.ncbi.nlm.nih...